Results 141 to 150 of about 10,477 (203)

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Etanercept for therapy-resistant macrophage activation syndrome

, 2008
Macrophage activation syndrome (MAS) is a severe, potentially fatal complication of childhood rheumatic diseases, especially systemic onset juvenile idiopathic arthritis (SoJIA). We report a 4-year-old girl with probable SoJIA who presented with MAS. She
Uensal, Erbil, YILMAZ, ŞEBNEM, Makay, BALAHAN, Tuerkyilmaz, Zeynep, ÖREN, HALE, Uenal, Nurettin   +5 more
core   +1 more source

Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs Do Not Arrest Bone Loss in Patients With Rheumatoid Arthritis: A Long‐Term Multicenter Observational Study

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2036-2049, October 2026.
Objective Osteoporosis causes fractures that further increase the disease burden of rheumatoid arthritis (RA); however, osteoporosis treatment rates remain low. Although several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi, Koshiro Sonomoto, Shingo Nakayamada, Hiroaki Tanaka, Atsushi Nagayasu, Satoshi Kubo, Ippei Miyagawa, Ayako Yamaguchi, Naoaki Ohkubo, Yasuyuki Todoroki, Yurie Satoh‐Kanda, Masanobu Ueno, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Satsuki Matsunaga, Hiroaki Tanaka, Masayuki Shinojima, Hiroki Kawamura, Kazuki Takahashi, Miyabi Ando, Kazuki Haru, Yusuke Miyazaki, Kentaro Hanami, Masao Nawata, Shunsuke Fukuyo, Keisuke Nakatsuka, Mikiko Tokunaga, Kazuyoshi Saito, Yoshiya Tanaka   +30 more
wiley   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, Volume 78, Issue 10, Page 2171-2178, October 2026.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Analysis of the Mediating Role of Cytokines in the Relationship Between Nonalcoholic Fatty Liver Disease and Cognitive Impairment After Ischemic Stroke

Brain and Behavior, Volume 16, Issue 10, October 2026.
This article reveals the mediating role of cytokine levels between non‐alcoholic fatty liver disease and post‐stroke cognitive impairment, providing new therapeutic targets for post‐stroke cognitive dysfunction. Abstract Objective To explore whether nonalcoholic fatty liver disease (NAFLD) is associated with poststroke cognitive impairment (PSCI) and ...
Xin Du, Jingwei Li
wiley   +1 more source

Beyond the Heart‐Lung Axis: A Review of the Crosstalk Between the Hemodynamic, Neurohormonal, and Immune Systems in Pulmonary Hypertension

Comprehensive Physiology, Volume 16, Issue 5, October 2026.
Pulmonary hypertension is driven by dynamic crosstalk beyond the physical connection between the heart and lung, involving neurohormonal systems, immune pathways, and peripheral organs. This review highlights how multisystem signaling contributes to disease progression and may reveal new diagnostic and therapeutic targets.
Alejandro A. Vega, Juliet M. Alfaro, David S. Pinto, Maryam Emamimeybodi, Soban Umar   +4 more
wiley   +1 more source

Drug‐Induced Liver Injury During Treatment With Tocilizumab: A Case Report of an Atypical Pattern Lesion

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
ABSTRACT Tocilizumab is an interleukin‐6 (IL‐6) receptor antagonist indicated for various rheumatologic conditions. While hepatotoxicity is a recognized adverse effect, it predominantly manifests as hepatocellular injury. We report a rare case of drug‐induced liver injury (DILI) presenting with a cholestatic pattern and cholangitis features in a 75 ...
Louis‐Edmond Barbaro, Nouha Ben Othman, Delphine Viard, Fanny Rocher, Elliot Ewig, Raja Mroue, Claire Amigues, Alexandre O. Gérard   +7 more
wiley   +1 more source

Review Article: Immune Effector Cell‐Mediated Enterocolitis Following CAR‐T Cell Therapy—Clinical Features, Pathophysiology and Management

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 8, Page 1046-1057, October 2026.
Immune effector cell‐mediated enterocolitis is an emerging complication of CAR‐T therapy. This review summarizes its epidemiology, pathophysiology, diagnosis, endoscopic and histopathologic features, and evidence‐based management, emphasizing early recognition, multidisciplinary intervention, and step‐up therapy.
John A. Damianos, Yi Lin, Zongming Eric Chen, Kenneth J. C. Lim, Navreet M. Chowla   +4 more
wiley   +1 more source

Advances in the treatment of systemic lupus erythematosus: Biologicals, small‐molecular agents, and cell‐depleting therapies coming to the clinic

Journal of Internal Medicine, Volume 300, Issue 4, Page 461-479, October 2026.
Abstract Systemic lupus erythematosus (SLE; lupus) remains a particular challenge for the practicing clinician on account of its chronic undulating and unpredictable course, its diverse manifestations, and—until recently—limited treatment options all associated with considerable downsides.
Ronald van Vollenhoven
wiley   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, Volume 78, Issue 10, Page 1317-1323, October 2026.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source